Protagenic Therapeutics Inc New (PTIX) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Protagenic Therapeutics Inc new  (NASDAQ: PTIX)


Protagenic Therapeutics Inc New's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Protagenic Therapeutics Inc New's ROA in the first quarter of 2026?
Protagenic Therapeutics Inc new achieved a return on average assets (ROA) of 89.64 % in its first quarter of 2026, this is above PTIX's average return on assets of -166.52%.
Protagenic Therapeutics Inc New assets over the 12 months ending in its first quarter of 2026 are valued at $6 million

Despite the company's net income deteriorating, Protagenic Therapeutics Inc New was able to improve its ROA compared to the fourth quarter of 2026.

However, within the Healthcare sector 7 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2026 from 4668 to 5037.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
I. Quarter		 (Mar 31 2026)
IV. Quarter		 (Dec 31 2025)
III. Quarter		 (Sep 30 2025)
II. Quarter		 (Jun 30 2025)
I. Quarter
Y / Y Total Assets Change -56.99 % 9227.31 % 126.55 % 231.68 % 343.11 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 5 1 -5 -9 -9
Return On Assets (TTM) 89.64 % 19.49 % -128.38 % -262.57 % -344.4 %
PTIX's Total Ranking # 5037 # 4668 # 4773 # 4836 # 5507
Total Assets (TTM) in million 3 12 4 5 7
Seq. Total Assets Change -76.97 % 174.04 % -11.43 % -23.04 % 4893.32 %
Seq. Net Income Change - 129.98 % - - -

PTIX's 5 Years Annual ROA >> Back to PTIX Management Effectiveness >> Compare PTIX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 3
Sector # 8
Overall # 35

Return On Assets Statistics
High Average Low
137.58 %
-166.52 %
-454.01 %
(Jun 30 2026)   (Dec 31 2015)





Financial Statements
Protagenic Therapeutics Inc New's Assets $ 3 million PTIX's Balance sheet
Protagenic Therapeutics Inc New's Income $ -1 million Quarterly PTIX's Income Statement
PTIX's Income by Division See PTIX's Income by Division



Annual Return On Assets (Mar 31 2026)
FY 2026		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 520.85 % -54.76 % -46.21 % -27.33 % 1157.82 %
Total Assets in million 12 2 4 8 11
Y / Y Net Income Change - - - - -
Net Income in million 1 -6 -5 -4 -5
Annual Return On Assets 11.27 % -282.49 % -115.66 % -44.24 % -40.89 %

PTIX's 5 Years Annual ROA >> Back to PTIX Management Effectiveness >> Compare PTIX ROA to its Competitors



Comment on PTIX's ROA in the fiscal year ending 2026
In the fiscal year 2026 ROA improved to 11.27 % compared to prior year, due to annual net income growth of % to $1.37 million, while value of Protagenic Therapeutics Inc New's overall assets grew just by 520.85 % to $12.14 million, compared to $12.14 a year before.


More Return On Assets Ratios
PTIX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PTIX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PTIX's Competitors
Subscribers only: Roa for Protagenic Therapeutics Inc New's Suppliers
Subscribers only: Return On Assets for PTIX's Customers

You may also want to know
PTIX's Roi PTIX's Inventory Turnover Ratio PTIX's Growth Rates PTIX's Dividend Comparisons
PTIX's Profitability Ratios PTIX's Asset Turnover Ratio PTIX's Dividend Growth
PTIX's Roe PTIX's Valuation Ratios PTIX's Financial Strength Ratios PTIX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Kyntra Bio Inc   156.80 %
Vor Biopharma Inc   154.23 %
Glucotrack Inc   151.40 %
Capforce Inc   141.40 %
Protagenic Therapeutics Inc new  137.58 %
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %

Date modified: 2026-08-20T08:17:23+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.